Tempus In Brief This Week: Burning Rock Biotech, Biocartis, NYGC, Eagle Genomics, Theradiag, OpGen, More News items for the week of Jan. 16, 2023. Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer This clinical study, called Sculptor, is the first research to emerge from a strategic collaboration between the companies on oncology therapeutics. In Brief This Week: OpGen, MDxHealth, Dante Genomics, More New items for the week of Oct. 24, 2022. Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug. Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients Tempus' xT platform will be used to identify patients likely to match for a trial assessing the efficacy of genetically informed treatments in certain pediatric cancers. Sep 7, 2022 Larger Liquid Biopsy Panels Loom, But Patient Benefit Still Uncertain Premium Jun 17, 2022 Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance Jun 9, 2022 Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients May 20, 2022 Tempus Takes on Precision Neuropsychiatry With New Research Dataset Premium May 9, 2022 Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial May 6, 2022 Tempus to Provide NGS Cancer Tests to US Department of Veterans Affairs Apr 12, 2022 Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial Apr 8, 2022 Tempus Sets Sights on Pathology Market With New Informatics, Research Network Premium Feb 8, 2022 Tempus Acquires Highline Sciences Nov 12, 2021 In Brief This Week: Caris Life Sciences, Psomagen, Tempus, CareDx, HTG Molecular, Epigenomics, More Sep 9, 2021 Cedars-Sinai, Tempus Partner on Molecular Database Initiative Aug 17, 2021 Tempus Submits PMA Application for Tumor Profiling Assay to FDA Jun 3, 2021 Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial May 21, 2021 New Products Posted to GenomeWeb: Tempus, Canopy Biosciences, Lonza, More Mar 3, 2021 Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership Feb 25, 2021 Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing Feb 12, 2021 New Products Posted to GenomeWeb: Tempus, Active Motif, Immudex, Zymo Research, More Jan 27, 2021 Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance Jan 13, 2021 Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity Jan 12, 2021 JP Morgan Healthcare Conference 2021, Day 1: Roche, Seer, 10x, Guardant, Hologic, Thermo Fisher Load More Breaking News Cancer Prognoses Informed by Module-Based Approach, Study Finds People in the News at Illumina, Centogene, BioSkryb New Products Posted to GenomeWeb: Bio-Rad, BD, Analytik Jena, BioMérieux Genetic Technologies to Raise A$5M in Direct Stock Offering In Brief This Week: SD Biosensors, Meridian, Oncocyte, Opko Health, GeneDx, More The Scan Study Reveals New Details About Genetics of Major Cause of Female Infertility Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency. Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis. Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven. White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.